LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Large B-cell Lymphoma
Related studies linked through entity extraction aliases.
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
- Status
- RECRUITING
- Phase
- PHASE2
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
- Status
- RECRUITING
- Phase
- N/A
Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT
- Status
- COMPLETED
- Phase
- PHASE2
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Status
- RECRUITING
- Phase
- PHASE3
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Glofitamab in Real Life
- Status
- RECRUITING
- Phase
- N/A
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
- Status
- RECRUITING
- Phase
- PHASE2
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
BHB & CAR-T for Lymphomas
- Status
- RECRUITING
- Phase
- NA
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Emapalumab Prevention of CAR-T Cell Associated Toxicities
- Status
- RECRUITING
- Phase
- PHASE2